Skip to main content

zusduri

Generic: mitomycin·Code: UGN-102

zusduri: sourced relationships with 1 company · 1 FDA decision.

zusduri evidence translation

What we can confirm

What it means

Source-backed records connect zusduri to URGN; that link alone does not prove the drug works.

What to watch

Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected

Prepared research question

How could zusduri → URGN affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

recurrent low-grade intermediate risk non-muscle invasive bladder cancer

Study sponsors

No additional listed-company sponsor is linked.

Dated Pipeline Records (1)
CompanyDated record stage
UroGen Pharma Ltd. (URGN)
developer · Reported 2026-03-02 · Current development: unknownSource
recurrent low-grade intermediate risk non-muscle invasive bl…
Approved
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE ZUSDURI™ is indicated for the treatment of adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). ZUSDURI is an alkylating drug indicated for the treatment of adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). ( 1 )(URGN)FDA ↗
NDA215793Type 3 - New Dosage FormStandardOtherPowder

Frequently asked questions

Which companies have sourced relationships with zusduri?

zusduri has dated SEC/FDA relationship records for UroGen Pharma Ltd..

What is zusduri's latest FDA decision?

The most recent tracked FDA decision for zusduri is Approval for 1 INDICATIONS AND USAGE ZUSDURI™ is indicated for the treatment of adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). ZUSDURI is an alkylating drug indicated for the treatment of adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). ( 1 ), dated June 12, 2025.